Physician profile
Sara E Covert
NPI 1780292995
$3,551.15
in general payments reported to CMS, 2019-2025
43 companies · $14.47 in 2025
The $14.47 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,446 · 2024: $90.38 · 2025: $14.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $424.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $422.30 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $258.70 | 2021 | |
| Incyte Corporation | $195.64 | 2021 | |
| Janssen Biotech, INC. | $189.56 | 2021 | |
| Merck Sharp & Dohme LLC | $183.44 | 2021 | |
| Genzyme Corporation | $180.12 | 2021 | |
| Tersera Therapeutics LLC | $156.12 | 2021 | |
| Acceleron Pharma, INC. | $116.21 | 2021 | |
| Glaxosmithkline, LLC. | $100.63 | 2021-2025 | Zejula |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Adaptive Biotechnologies Corporation | $90.38 | 2024 | Clonoseq |
| Daiichi Sankyo INC. | $83.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $74.77 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Covert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.